Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Matok Ilan

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. CNS Drugs 2021;35(3):305-316.

(2) Masarwa R, Perlman A, Levine H, Matok I. Masarwa et al. Respond to “The Disillusionment of Developmental Origins of Health and Disease (DOHaD) Epidemiology”. Am J Epidemiol 2021;189(1):6-7.

(3) Azran C, Hanhan-Shamshoum N, Irshied T, Ben-Shushan T, Dicker D, Dahan A, et al. Hypothyroidism and levothyroxine therapy following bariatric surgery: a systematic review, meta-analysis, network meta-analysis, and meta-regression. Surg Obes Relat Dis 2021.

(4) Zingerman B, Ziv D, Feder Krengel N, Korzets A, Matok I. Cessation of Bezafibrate in patients with chronic kidney disease improves renal function. Sci Rep 2020;10(1).

(5) Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I. The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database. Int J Obes 2020;44(5):1021-1027.

(6) Rotshild V, Perlman A, Matok I. Reply: “Association Between Lung Cancer and Calcium Channel Blockers Use”. Ann Pharmacother 2019;53(10):1074.

(7) Rotshild V, Azoulay L, Feldhamer I, Perlman A, Muszkat M, Matok I. Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study. Pharmacotherapy 2019;39(6):690-696.

(8) Hirsh Raccah B, Rottenstreich A, Zacks N, Matok I, Danenberg HD, Pollak A, et al. Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients. J Thromb Thrombolysis 2019;47(4):550-557.

(9) Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Raccah B, Horwitz E, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis 2019;47(4):590-595.

(10) Rotshild V, Azoulay L, Feldhamer I, Perlman A, Glazer M, Muszkat M, et al. Calcium Channel Blockers and the Risk for Lung Cancer: A Population-Based Nested Case-Control Study. Ann Pharmacother 2019;53(5):445-452.

(11) Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, et al. Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Drug Saf 2019;42(4):529-538.

(12) Kabiri D, Masarwy R, Schachter-Safrai N, Masarwa R, Hirsh Raccah B, Ezra Y, et al. Trial of labor after cesarean delivery in twin gestations: systematic review and meta-analysis. Am J Obstet Gynecol 2019;220(4):336-347.

(13) Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am J Obstet Gynecol 2019;220(1):57.e1-57.e13.

(14) Matok I, Masarwa R, Levine H, Perlman A. FOUR AUTHORS REPLY. Am J Epidemiol 2018;187(12):2718.

(15) Hirsh Raccah B, Rottenstreich A, Zacks N, Muszkat M, Matok I, Perlman A, et al. Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. J Thromb Thrombolysis 2018;46(4):521-527.

(16) Raccah BH, Perlman A, Zwas DR, Hochberg-Klein S, Masarwa R, Muszkat M, et al. Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis. Ann Pharmacother 2018;52(11):1135-1142.

(17) Tsvirkun D, Ben-Nun Y, Merquiol E, Zlotver I, Meir K, Weiss-Sadan T, et al. CT Imaging of Enzymatic Activity in Cancer Using Covalent Probes Reveal a Size-Dependent Pattern. J Am Chem Soc 2018;140(38):12010-12020.

(18) Perlman A, Hirsh Raccah B, Matok I, Muszkat M. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. J Card Fail 2018;24(8):533-536.

(19) Masarwa R, Levine H, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to acetaminophen and risk for attention deficit hyperactivity disorder and autistic spectrum disorder: A systematic review,meta-analysis, and meta-regression analysis of cohort studies. Am J Epidemiol 2018;187(8):1817-1827.

(20) Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob Agents Chemother 2018;62(6).

(21) Rotshild V, Azoulay L, Zarifeh M, Masarwa R, Hirsh-Raccah B, Perlman A, et al. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies. Drug Saf 2018;41(6):555-564.

(22) Ziv A, Masarwa R, Perlman A, Ziv D, Matok I. Pregnancy Outcomes Following Exposure to Quinolone Antibiotics – a Systematic-Review and Meta-Analysis. Pharm Res 2018;35(5).

(23) Treves N, Perlman A, Geron LK, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age Ageing 2018;47(2):201-208.

(24) Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 2017;27(12):1108-1113.

(25) Zenziper Straichman Y, Kurnik D, Matok I, Halkin H, Markovits N, Ziv A, et al. Prescriber response to computerized drug alerts for electronic prescriptions among hospitalized patients. Int J Med Informatics 2017;107:70-75.

(26) Shlomo M, Gorodischer R, Daniel S, Wiznitzer A, Matok I, Fishman B, et al. The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study. Drug Saf 2017;40(11):1147-1155.

(27) Matok I, Elizur A, Perlman A, Ganor S, Levine H, Kozer E. Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness. Ann Pharmacother 2017;51(3):239-244.

(28) Masarwa R, Paret G, Perlman A, Reif S, Raccah BH, Matok I. Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: A systematic review, meta-analysis, and trial sequential analysis. Crit Care 2017;21(1).

(29) Koren G, Clark S, Hankins GDV, Caritis SN, Umans JG, Miodovnik M, et al. Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. BMC Pregnancy Childbirth 2016;16(1).

(30) Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I. Major Bleeding and Hemorrhagic Stroke with Direct Oral Anticoagulants in Patients with Renal Failure Systematic Review and Meta-Analysis of Randomized Trials. Chest 2016;149(6):1516-1524.

(31) Perlman A, Shah RC, Bennett DA, Buchman AS, Matok I. Antihypertensive and Statin Medication Use and Motor Function in Community-Dwelling Older Adults. J Am Med Dir Assoc 2016;17(3):220-224.

(32) Koren G, Clark S, Hankins GDV, Caritis SN, Umans JG, Miodovnik M, et al. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy Childbirth 2015;15(1).

(33) Lapi F, Azoulay L, Kezouh A, Benisty J, Matok I, Mugelli A, et al. The use of antidepressants and the risk of chronic atrial fibrillation. J Clin Pharmacol 2015;55(4):423-430.

(34) Matok I, Clark S, Caritis S, Miodovnik M, Umans JG, Hankins G, et al. Studying the antiemetic effect of vitamin B6 for morning sickness: pyridoxine and pyridoxal are prodrugs. J Clin Pharmacol 2014;54(12):1429-1433.

(35) Matok I, Azoulay L, Yin H, Suissa S. Immortal time bias in observational studies of drug effects in pregnancy. Birth Defects Res Part A Clin Mol Teratol 2014;100(9):658-662.

(36) Arien-Zakay H, Gincberg G, Nagler A, Cohen G, Liraz-Zaltsman S, Trembovler V, et al. Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury. J Neurotrauma 2014;31(16):1405-1416.

(37) Matok I, Perlman A. Cohort study: Metoclopramide in pregnancy: No association with adverse fetal and neonatal outcomes. Evid -Based Med 2014;19(3):115.

(38) Goldberg O, Koren G, Landau D, Lunenfeld E, Matok I, Levy A. Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations. J Clin Pharmacol 2013;53(9):991-995.

(39) Lam J, Kelly L, Matok I, Ross CJD, Carleton BC, Hayden MR, et al. Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. Ther Drug Monit 2013;35(4):466-472.

(40) Matok I, Umans J, Feghali MN, Clark S, Caritis S, Miodovnik M, et al. Characteristics of women with nausea and vomiting of pregnancy who chose to continue compassionate use of placebo after a randomised trial. J Obstet Gynaecol 2013;33(6):557-560.

(41) Dinur AB, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, et al. Fetal safety of macrolides. Antimicrob Agents Chemother 2013;57(7):3307-3311.

(42) Matok I, Clark S, Caritis S, Miodovnik M, Umans J, Hankins G, et al. Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. J Clin Pharmacol 2013;53(3):334-338.

(43) Orbach H, Matok I, Gorodischer R, Sheiner E, Daniel S, Wiznitzer A, et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013;208(4):301.e1-301.e6.

(44) Natekar A, Matok I, Walasek P, Rao C, Clare-Fasullo G, Koren G. Cocaethylene as a hair biomarker to predict heavy alcohol exposure among cocaine users. J Popul ther Clin Pharmacol 2012;19(3):e466-e472.

(45) Kennedy DA, Stern SJ, Matok I, Moretti ME, Sarkar M, Adams-Webber T, et al. Folate intake, MTHFR polymorphisms, and the risk of colorectal cancer: A systematic review and meta-analysis. J Cancer Epidemiol 2012.

(46) Daniel S, Matok I, Gorodischer R, Koren G, Uziel E, Wiznitzer A, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 2012;39(11):2163-2169.

(47) Costantine MM, Matok I, Chiossi G, Clark S, Miodovnik M, Umans JG, et al. Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. Ther Drug Monit 2012;34(5):569-573.

(48) Walfisch A, Matok I, Sermer C, Koren G. Weight-depression association in a high-risk maternal population. J Matern -Fetal Neonatal Med 2012;25(7):1017-1020.

(49) Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 2012;33(3):265-268.

(50) Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012;57(3):699-705.

(51) Stern SJ, Matok I, Kapur B, Koren G. Dosage Requirements for Periconceptional Folic Acid Supplementation: Accounting for BMI and Lean Body Weight. J Obstet Gynaecol Can 2012;34(4):374-378.

(52) Levy A, Matok I, Gorodischer R, Sherf M, Wiznitzer A, Uziel E, et al. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: The folic acid antagonists. J Clin Pharmacol 2012;52(1):78-83.

(53) VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VMGJ, et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: A pilot study. Ther Drug Monit 2011;33(4):425-432.

(54) Brosh K, Matok I, Sheine E, Koren G, Wiznitzer A, Gorodischer R, et al. Teratogenic determinants of first- trimester exposure to antiepileptic medications. J Popul ther Clin Pharmacol 2011;18(1):e89-e98.

(55) Walfisch A, Sermer C, Matok I, Koren G, Einarson A. Screening for depressive symptoms. Can Fam Phys 2011;57(7):777-778.

(56) Stern SJ, Matok I, Kapur B, Koren G. A comparison of folic acid pharmacokinetics in obese and nonobese women of childbearing age. Ther Drug Monit 2011;33(3):336-340.

(57) Matok I, Levy A, Gorodischer R, Lunenfeld E, Limony Y, Koren G. BeMORE: A novel method for detection of adverse fetal effects induced by drugs. Curr Drug Saf 2011;6(1):40-42.

(58) Kennedy DA, Stern SJ, Moretti M, Matok I, Sarkar M, Nickel C, et al. Folate intake and the risk of colorectal cancer: A systematic review and meta-analysis. Cancer Epidemiol 2011;35(1):2-10.

(59) Diamond SA, Matok I. Pharmacists' anticipated pain compared to experienced pain associated with insulin pen injection and fingertip lancing. Can J Diabetes 2011;35(3):282-286.

(60) Matok I, Pupco A, Koren G. Drug exposure in pregnancy and heart defects. J Cardiovasc Pharmacol 2011;58(1):20-24.

(61) Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of Teratogenic Risk and the Rated Likelihood of Pregnancy Termination: Association with Maternal Depression. Can J Psychiatry 2011;56(12):761-767.

(62) Koren G, Sakaguchi S, Klieger C, Kazmin A, Osadchy A, Yazdani-Brojeni P, et al. Toward improved pregnancy labelling. J Popul ther Clin Pharmacol 2010;17(3):e349-e357.

(63) Koren G, Sakaguchi S, Klieger C, Kazmin A, Osadchy A, Yazdani-Brojeni P, et al. Toward improved pregnancy labelling. Can J Clin Pharmacol 2010;17(3):e349-e357.

(64) Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Uziel E, et al. The safety of H2-blockers use during pregnancy. J Clin Pharmacol 2010;50(1):81-87.

(65) Klieger-Grossmann C, Chitayat D, Lavign S, Kao K, Garcia-Bournissen F, Quinn D, et al. Prenatal Exposure to Mycophenolate Mofetil: An Updated Estimate. J Obstet Gynaecol Can 2010;32(8):794-797.

(66) Matok I, Gorodischer R, Koren G, Landau D, Wiznitzer A, Levy A. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol 2009;68(6):956-962.

(67) Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. Obstet Gynecol Surv 2009;64(10):637-638.

(68) Matok I, Paret G. Authors' reply. Ann Pharmacother 2009;43(7-8):1376.

(69) Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. New Engl J Med 2009;360(24):2528-2535.

(70) Matok I, Rubinshtein M, Levy A, Vardi A, Leibovitch L, Mishali D, et al. Terlipressin for children with extremely low cardiac output after open heart surgery. Ann Pharmacother 2009;43(3):423-429.

(71) Matok I, Paret G. Arginine-vasopressin as a rescue therapy in children with cardiocirculatory failure [2]. Crit Care Med 2007;35(7):1800.

(72) Vardi A, Efrati O, Levin I, Matok I, Rubinstein M, Paret G, et al. Prevention of potential errors in resuscitation medications orders by means of a computerised physician order entry in paediatric critical care. Resuscitation 2007;73(3):400-406.

(73) Leibovitch L, Matok I, Paret G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs 2007;67(1):57-73.

(74) Matok I, Vardi A, Augarten A, Efrati O, Leibovitch L, Rubinshtein M, et al. Beneficial effects of terlipressin in prolonged pediatric cardiopulmonary resuscitation: A case series. Crit Care Med 2007;35(4):1161-1164.

(75) Augarten A, Zaslansky R, Matok Pharm I, Minuskin T, Lerner-Geva L, Hirsh-Yechezkel G, et al. The impact of educational intervention programs on pain management in a pediatric emergency department. Biomed Pharmacother 2006;60(7):299-302.

(76) Matok I, Vard A, Efrati O, Rubinshtein M, Vishne T, Leibovitch L, et al. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock 2005;23(4):305-310.

(77) Matok I, Leibovitch L, Vardi A, Adam M, Rubinshtein M, Barzilay Z, et al. Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatr Crit Care Med 2004;5(2):116-118.

(78) Efrati O, Modan-Moses D, Vardi A, Matok I, Bazilay Z, Paret G. Intravenous arginine vasopressin in critically ill children: Is it beneficial? Shock 2004;22(3):213-217.

(79) Bar-Lev MRR, Maayan-Metzger A, Matok I, Heyman Z, Sivan E, Kuint J. Short-term outcomes in low birth weight infants following antenatal exposure to betamethasone versus dexamethasone. Obstet Gynecol 2004;104(3):484-488.

(80) Leibovitch L, Kenet G, Mazor K, Matok I, Vardi A, Barzilay Z, et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003;4(4):444-446.

(81) Leibovitch L, Efrati O, Vardi A, Matok I, Barzilay Z, Paret G. Intractable hypotension in septic shock: Successful treatment with vasopressin in an infant. Isr Med Assoc J 2003;5(8):596-598.